14 June 2017 - NICE has published a Final Appraisal Consultation document for patients with Hodgkin's lymphoma and an Appraisal Consultation Document for patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Brentuximab vedotin is recommended as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:

• they have relapsed or refractory disease after autologous stem cell transplant and
  
• the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.
  

Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:

• they have relapsed or refractory disease after at least 2 previous therapies and
  
• they cannot have autologous stem cell transplant or multi-agent chemotherapy and
  
• the conditions of the managed access agreement are followed.

NICE is minded not to recommend brentuximab vedotin, within its marketing authorisation, for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.

Read Final Appraisal Determination

Read Appraisal Consultation Document